NCT03017430View on ClinicalTrials.gov

Pregabalin for Opiate Withdrawal Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Opioid Withdrawal
Interventions
DRUG

Pregabalin

Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).

DRUG

Clonidine

Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)

DRUG

Doxylamin

DRUG

Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)

Trial Locations (1)

192019

St.-Petersburg Bekhterev Reserach Psychoneurological Institute, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg Bekhterev Research Psychoneurological Institute

OTHER

NCT03017430 - Pregabalin for Opiate Withdrawal Syndrome | Biotech Hunter | Biotech Hunter